Onkológia 1/2008

SYSTEMIC TREATMENT FOR ADVANCED HEPATOCELLULAR CANCER

Hepatocelullar carcinoma (HCC) is the fifth most common cancer and the third most common cause of cancer-related death. A majority of HCC patients (> 80 %) presents with advanced or unresectable disease. Even for those with resected disease, the recurrence rate can be as high as 50 % at 2 years. The patients hepatic reserve, as indicated by Child-Pugh classification, often dictates therapeutic option. The purpose of this article is to discuss the most appropriate aproaches using chemotherapy, imunochemotherapy, hormonal treatment and explaining of some new options of targeted therapy, which has been recently approved and briefly describe principles of supportive care.

Keywords: hepatocelullar cancer, chemotherapy, imunotherapy, hormonal treatment, targetet therapy, sorafenib, supportive care